Abnova Taiwan Corp
Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company's products portfolio includes SARS-CoV/CoV-2 DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag… Read more
Abnova Taiwan Corp (4133) - Total Liabilities
Latest total liabilities as of September 2025: NT$74.25 Million TWD
Based on the latest financial reports, Abnova Taiwan Corp (4133) has total liabilities worth NT$74.25 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Abnova Taiwan Corp - Total Liabilities Trend (2008–2024)
This chart illustrates how Abnova Taiwan Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Abnova Taiwan Corp Competitors by Total Liabilities
The table below lists competitors of Abnova Taiwan Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Moller Y Perez
SN:MOLLER
|
Chile | CL$264.82 Billion |
|
M-POWER INFORMATION Co., LTD.
TWO:6874
|
Taiwan | NT$770.34 Million |
|
Sunfon Construction Co Ltd
TWO:5514
|
Taiwan | NT$3.62 Billion |
|
Dong-A Hwa Sung Co.Ltd
KQ:041930
|
Korea | ₩133.83 Billion |
|
MEGA International Development Co Ltd
TWO:5529
|
Taiwan | NT$3.93 Billion |
|
Sernova Biotherapeutics Inc
XETRA:PSH0
|
Germany | €25.84 Million |
|
Engtex Group Bhd
KLSE:5056
|
Malaysia | RM729.90 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Abnova Taiwan Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abnova Taiwan Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abnova Taiwan Corp (2008–2024)
The table below shows the annual total liabilities of Abnova Taiwan Corp from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$91.65 Million | +32.01% |
| 2023-12-31 | NT$69.42 Million | -16.19% |
| 2022-12-31 | NT$82.83 Million | +16.19% |
| 2021-12-31 | NT$71.29 Million | -14.61% |
| 2020-12-31 | NT$83.49 Million | +16.63% |
| 2019-12-31 | NT$71.59 Million | +5.64% |
| 2018-12-31 | NT$67.77 Million | -14.28% |
| 2017-12-31 | NT$79.05 Million | +9.71% |
| 2016-12-31 | NT$72.06 Million | -12.50% |
| 2015-12-31 | NT$82.35 Million | +5.37% |
| 2014-12-31 | NT$78.15 Million | +41.02% |
| 2013-12-31 | NT$55.42 Million | -12.20% |
| 2012-12-31 | NT$63.12 Million | -25.31% |
| 2011-12-31 | NT$84.51 Million | +31.55% |
| 2010-12-31 | NT$64.24 Million | -32.62% |
| 2009-12-31 | NT$95.34 Million | -15.41% |
| 2008-12-31 | NT$112.71 Million | -- |